Hyaluronic acid as a treatment for ankle osteoarthritis

Shu-Fen Sun, Yi-Jiun Chou, Chien-Wei Hsu, Wen-Ling Chen, Shu-Fen Sun, Yi-Jiun Chou, Chien-Wei Hsu, Wen-Ling Chen

Abstract

Viscosupplementation refers to the concept of synovial fluid replacement with intra-articular injections of hyaluronic acid (HA) for the relief of pain associated with osteoarthritis (OA). Intra-articular viscosupplementation was approved by the Food and Drug Administration (FDA) in 1997. It is currently indicated only for the treatment of pain associated with knee OA. However, OA can occur in several of the weight-bearing joints of the foot and ankle. Ankle OA produces chronic disability that directly impacts the quality of life. There is only limited published literature relating to the use of HA in the ankle. This paper will review the authors' experience, indications, clinical outcomes, and complications of viscosupplementation therapy in patients with ankle OA.

Figures

Fig. 1
Fig. 1
Ankle joint injection
Fig. 2
Fig. 2
Ankle joint injection

References

    1. Creamer P, Hochberg MC. Osteoarthritis. Lancet. 1997;350:503–508. doi: 10.1016/S0140-6736(97)07226-7.
    1. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–646.
    1. Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect. 1998;47:487–504.
    1. Adams ME. An analysis of clinical studies of the use of cross linked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:16–18.
    1. Frizziero L, Govoni E, Bachin P. Intraarticular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol. 1998;16:441–449.
    1. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3(4):213–225. doi: 10.1016/S1063-4584(05)80013-5.
    1. Belcher C, Yaqub R, Fawthrop F, Bayliss M, et al. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann Rheum Dis. 1997;56:299–307. doi: 10.1136/ard.56.5.299.
    1. Engström-Laurent A. Hyaluronan in joint disease. J Int Med. 1997;242:57–60. doi: 10.1046/j.1365-2796.1997.00174.x.
    1. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:4–9.
    1. Rydell N, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthop. 1971;80:25–32. doi: 10.1097/00003086-197110000-00006.
    1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update. Arthritis Rheum. 2000;43:1905–1915. doi: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>;2-P.
    1. Kelly MA, Goldberg VM, Healy WL, et al. Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics. 2003;26:1064–1081.
    1. Pleimann JH, Davis WH, Cohen BE, et al. Viscosupplementation for the arthritic ankle. Foot Ankle Clin. 2002;7(3):489–494. doi: 10.1016/S1083-7515(02)00021-9.
    1. Wang CW, Gao LH, Jin XY, et al. Clinical study of sodium hyaluronate in supplementary treatment of comminuted fracture of ankle. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2002;16(1):21–22.
    1. Salk RS, Chang TJ, D’Costa WF, et al. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. J Bone Jt Surg Am. 2006;88:295–302. doi: 10.2106/JBJS.E.00193.
    1. Sun SF, Chou YJ, Hsu CW, et al. Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study. Osteoarthritis Cartilage. 2006;14(9):867–874. doi: 10.1016/j.joca.2006.03.003.
    1. Conrozier T, Bertin P, Mathieu P, et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label, multicentre, pilot study. Clin Exp Rheumatol. 2003;21:605–610.
    1. Migliore A, Tormenta S, Martin LSM, et al. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol. 2005;24:285–289. doi: 10.1007/s10067-004-1009-1.
    1. Tikiz C, Unlu Z, Sener A, et al. Comparison of efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. 2005;24:244–250. doi: 10.1007/s10067-004-1013-5.
    1. Labbe M, Ridgeland E, Savoie FH, et al. The short-term efficacy of hyaluronic acid injections for the treatment of degenerative arthrosis of the shoulder. Arthroscopy. 2003;19:S13–S18.
    1. Marshall KW. Intra-articular hyaluronan therapy. Foot Ankle Clin N Am. 2003;8:221–232. doi: 10.1016/S1083-7515(03)00046-9.
    1. Clarke S, Lock V, Duddy J, et al. Intra-articular hylan G-F 20 in the management of patellofemoral osteoarthritis of the knee. The Knee. 2005;12:57–62. doi: 10.1016/j.knee.2004.03.002.
    1. Roux C, Fontas E, Breuil V, et al. Injection of intra-articular sodium hyaluronidate (Sinovial) into the carpometacarpal joint of the thumb (CMC1) in osteoarthritis. A prospective evaluation of efficacy. Jt Bone Spine. 2007;74(4):368–372. doi: 10.1016/j.jbspin.2006.08.008.
    1. Kellgren JH, Lawrence JS. Atlas of standard radiographs: the epidemiology of chronic rheumatism. Oxford, UK: Blackwell Scientific Publications; 1963.
    1. Hammesfahr JF, Knopf AB, Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop. 2003;32:277–283.
    1. Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000;8:277–284.
    1. Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from a clinical practice in Canada. J Rheumatol. 1996;23:1579–1585.
    1. Kemper F, Gebhardt U, Meng T, et al. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21:1261–1269. doi: 10.1185/030079905X56501.
    1. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin. 2003;19:575–580. doi: 10.1185/030079903125002243.
    1. Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2006;19:19–27.
    1. Hamburger MI, Lakhanpal S, Mooar PA, et al. Intraarticular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003;32:296–309. doi: 10.1053/sarh.2002.50008.
    1. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop. 2004;419:130–137. doi: 10.1097/00003086-200402000-00021.
    1. Marino AA, Waddell DD, Kolomytkin OV, et al. Assessment of immunologic mechanisms for flare reactions to Synvisc. Clin Orthop. 2006;442:187–194. doi: 10.1097/01.blo.0000185031.86478.a8.
    1. Leopold SS, Warme WJ, Pettis PD, et al. Increased frequency of acute local reaction to intra-articular hylan G-F 20 in patients receiving more than one course of treatment. J Bone Jt Surg. 2002;84A:1619–1623.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner